 The month of May is designated as Hepatitis Awareness Month in the United States, and May 19th is Hepatitis Testing Day. During May, CDC, along with public health partners worked to shed light on the impact of these hidden epidemics by raising awareness of viral hepatitis while encouraging testing and vaccination. Hepatitis Awareness Month activities helped to improve everyone’s understanding of viral hepatitis transmission and risk factors as well as decrease social stigma against viral hepatitis.
For more information, please visit:
CDC's Hepatitis Awareness Month
What is Viral Hepatitis? (CDC)
Hepatitis B FAQs (CDC)
Have you heard of the PneumoRecs VaxAdvisor mobile app?
This handy app helps vaccination providers quickly and easily determine which pneumococcal vaccines a patient needs and when. The app incorporates recommendations for all ages.
Users simply:
- Enter a patient’s age.
- Note if the patient has specific underlying medical conditions.
- Answer questions about the patient’s pneumococcal vaccination history.
Using the information entered, the app provides patient-specific guidance consistent with the immunization schedule recommended by the U.S. Advisory Committee on Immunization Practices (ACIP).
For information on how to download the app, please visit:
CDC's VaxAdvisor |
 MIP is happy to announce that the PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine) is now available through ImmPact for providers to order.
On October 20, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
PENBRAYA combines the components from two meningococcal vaccines, Trumenba® (meningococcal group B vaccine) and Nimenrix® (meningococcal groups A, C, W-135, and Y conjugate vaccine) to help protect against the five most common meningococcal serogroups that cause the majority of invasive meningococcal disease (IMD) globally.
On October 25, 2023, the Advisory Committee on Immunization Practices recommended a new pentavalent meningococcal vaccine as an option for adolescents and young adults.
Pfizer’s MenABCWY vaccine may be used when both MenACWY and MenB are indicated at the same visit*.
* Healthy individuals aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccination, 2) individuals aged 10 years and older at increased risk of meningococcal disease (e.g., due to persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia) due for both vaccines.
MIP-enrolled sites must ensure the following:
- MIP-supplied vaccines are administered to eligible children or adults (317) only
- Eligibility screening must be done at every vaccine encounter
- Eligibility must be documented at every vaccine encounter
- VFC vaccine is only given to children 0 -18 years of age.
- Adult 317 vaccine is only given to adults 19 years and older who are under or uninsured.
- Vaccine loss and waste are minimized and documented.
- Fraud and abuse does not occur.
- MIP vaccine inventory is accurately reported at least every 14 days
(recommended weekly).
- Monitor, read and record the minimum and maximum temperatures of
the units (refrigerators and freezers) at the beginning of each workday.
For more complete information on program requirements, please see MIP's Policy and Procedure Manual. |
